Patents by Inventor Paul R. Sleath
Paul R. Sleath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20030095971Abstract: Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.Type: ApplicationFiled: October 30, 2001Publication date: May 22, 2003Applicant: Corixa CorporationInventors: Alexander Gaiger, Patricia D. McNeill, Molly Smithgall, Gus Moulton, Thomas S. Vedvick, Paul R. Sleath, Sally P. Mossman, Lawrence S. Evans, A. Gregory Spies, Jeremy Boydston
-
Publication number: 20030082196Abstract: Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.Type: ApplicationFiled: February 15, 2001Publication date: May 1, 2003Inventors: Alexander Gaiger, Martin A. Cheever, Patricia D. McNeill, Molly Smithgall, Gus Moulton, Thomas S. Vedvick, Paul R. Sleath
-
Publication number: 20030072767Abstract: Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.Type: ApplicationFiled: August 24, 2001Publication date: April 17, 2003Inventors: Alexander Gaiger, Patricia D. McNeill, Molly Smithgall, Gus Moulton, Thomas S. Vedvick, Paul R. Sleath, Sally Mossman, Lawrence Evans, A. Gregory Spies, Jeremy Boydston
-
Publication number: 20030068327Abstract: Compounds and methods for the diagnosis and treatment of HSV infection are provided. The compounds comprise polypeptides that contain at least one antigenic portion of an HSV polypeptide and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits are also provided comprising such polypeptides and/or DNA sequences and a suitable detection reagent for the detection of HSV infection in patients and in biological samples.Type: ApplicationFiled: April 11, 2002Publication date: April 10, 2003Applicant: Corixa CorporationInventors: Nancy Ann Hosken, Patrick McGowan, Paul R. Sleath, Sally P. Mossman, Lawrence S. Evans, Ryan M. Swanson, Patricia D. McNeill
-
Patent number: 6537555Abstract: Compounds and methods for the diagnosis and treatment of HSV infection are provided. The compounds comprise polypeptides that contain at least one antigenic portion of an HSV polypeptide and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits are also provided comprising such polypeptides and/or DNA sequences and a suitable detection reagent for the detection of HSV infection in patients and in biological samples.Type: GrantFiled: June 28, 2001Date of Patent: March 25, 2003Assignee: Corixa CorporationInventors: Nancy A. Hosken, Craig H. Day, Davin C. Dillon, Patrick McGowan, Paul R. Sleath
-
Publication number: 20030023036Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer.Type: ApplicationFiled: February 13, 2002Publication date: January 30, 2003Applicant: Corixa CorporationInventors: Raymond L. Houghton, Paul R. Sleath, David H. Persing
-
Publication number: 20020169136Abstract: Compounds and methods for the diagnosis and treatment of B. microti infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a B. microti antigen and DNA sequences encoding such polypeptides. Antigenic epitopes of such antigens are also provided, together with pharmaceutical compositions and vaccines comprising such polypeptides, DNA sequences or antigenic epitopes. Diagnostic kits containing such polypeptides, DNA sequences or antigenic epitopes and a suitable detection reagent may be used for the detection of B. microti infection in patients and biological samples. Antibodies directed against such polypeptides and antigenic epitopes are also provided.Type: ApplicationFiled: April 5, 1999Publication date: November 14, 2002Inventors: STEVEN G. REED, MICHAEL J. LODES, RAYMOND L. HOUGHTON, PAUL R. SLEATH, PATRICIA D. MCNEIL
-
Patent number: 6451315Abstract: Compounds and methods for the diagnosis and treatment of B. microti infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a B. microti antigen, DNA sequences encoding such polypeptides, and fusion proteins comprising such polypeptides. Antigenic epitopes of such antigens are also provided, together with pharmaceutical compositions and vaccines comprising such polypeptides, DNA sequences, fusion proteins or antigenic epitopes. Diagnostic kits containing such polypeptides, DNA sequences, fusion proteins or antigenic epitopes and a suitable detection reagent may be used for the detection of B. microti infection in patients and biological samples. Antibodies directed against such polypeptides and antigenic epitopes are also provided.Type: GrantFiled: March 17, 2000Date of Patent: September 17, 2002Assignee: Corixa CorporationInventors: Steven G. Reed, Michael J. Lodes, Raymond L. Houghton, Paul R. Sleath, Patricia D. McNeill
-
Publication number: 20020090610Abstract: Compounds and methods for the diagnosis and treatment of HSV infection are provided. The compounds comprise polypeptides that contain at least one antigenic portion of an HSV polypeptide and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits are also provided comprising such polypeptides and/or DNA sequences and a suitable detection reagent for the detection of HSV infection in patients and in biological samples.Type: ApplicationFiled: June 28, 2001Publication date: July 11, 2002Inventors: Nancy A. Hosken, Craig H. Day, Davin C. Dillon, Patrick McGowan, Paul R. Sleath
-
Patent number: 6312731Abstract: A composition for inducing or potentiating an immune response, preferably a CTL, T helper cell, or neutralizing antibody response in a subject, comprising an antigen and/or a non-antigen bioactive agent capable of inducing or potentiating such an immune response encapsulated in a polymeric composition, wherein the polymeric composition comprises a blend of (a) a polymer present in an amount sufficient to provide structural integrity to the polymeric composition, and (b) a rapidly biodegradable component, a rapidly dissolving component, a rapidly swelling component, or a component that causes osmotic rupture of the encapsulated polymeric composition is disclosed. Single polymer compositions for achieving such an immune response are also disclosed. Methods for inducing or potentiating a CTL, T helper cell or neutralizing antibody response using the above-identified compositions are disclosed.Type: GrantFiled: August 28, 1998Date of Patent: November 6, 2001Assignees: Southern Research Institute, Corixa CorporationInventors: Jay K. Staas, Thomas R. Tice, Syamal Raychaudhuri, Paul R. Sleath
-
Patent number: 6306396Abstract: Compounds and methods for the diagnosis and treatment of B. microti infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a B. microti antigen and DNA sequences encoding such polypeptides. Antigenic epitopes of such antigens are also provided, together with pharmaceutical compositions and vaccines comprising such polypeptides, DNA sequences or antigenic epitopes. Diagnostic kits containing such polypeptides, DNA sequences or antigenic epitopes and a suitable detection reagent may be used for the detection of B. microti infection in patients and biological samples. Antibodies directed against such polypeptides and antigenic epitopes are also provided.Type: GrantFiled: October 1, 1996Date of Patent: October 23, 2001Assignee: Corixa CorporationInventors: Steven G. Reed, Michael J. Lodes, Raymond Houghton, Paul R. Sleath
-
Publication number: 20010029295Abstract: Compounds and methods for the diagnosis and treatment of B. microti infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a B. microti antigen and DNA sequences encoding such polypeptides. Antigenic epitopes of such antigens are also provided, together with pharmaceutical compositions and immunogenic compositions comprising such polypeptides, DNA sequences or antigenic epitopes. Diagnostic kits containing such polypeptides, DNA sequences or antigenic epitopes and a suitable detection reagent may be used for the detection of B. microti infection in patients and biological samples. Antibodies directed against such polypeptides and antigenic epitopes are also provided.Type: ApplicationFiled: December 13, 2000Publication date: October 11, 2001Inventors: Steven G. Reed, Michael J. Lodes, Raymond L. Houghton, Paul R. Sleath, Patricia D. McNeill
-
Patent number: 6183976Abstract: Compounds and methods for the diagnosis and treatment of B. microti infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a B. microti antigen and DNA sequences encoding such polypeptides. Antigenic epitopes of such antigens are also provided, together with pharmaceutical compositions and vaccines comprising such polypeptides, DNA sequences or antigenic epitopes. Diagnostic kits containing such polypeptides, DNA sequences or antigenic epitopes and a suitable detection reagent may be used for the detection of B. microti infection in patients and biological samples. Antibodies directed against such polypeptides and antigenic epitopes are also provided.Type: GrantFiled: April 24, 1997Date of Patent: February 6, 2001Assignee: Corixa CorporationInventors: Steven G. Reed, Michael J. Lodes, Raymond Houghton, Paul R. Sleath
-
Patent number: 6136787Abstract: There is disclosed an isolated polypeptide and derivatives thereof having protease biological activity for human precursor IL-1.beta. and for a substrate comprising:R.sub.1 -Asp-R.sub.2 -R.sub.3wherein R.sub.1 and R.sub.3 are independently any D or L isomer amino acid, R.sub.2 is Ala or Gly, and wherein the specific protease cleavage site is between Asp and R.sub.2. Inhibitor compounds, compositions and methods for inhibiting Interleukin 1.beta. protease activity are also disclosed. The inhibitor compounds comprise an amino acid sequence of from 1 to about 5 amino acids having an N-terminal blocking group and a C-terminal Asp residue connected to an electronegative leaving group, wherein the amino acid sequence corresponds to the sequence Ala-Tyr-Val-His-Asp.Type: GrantFiled: March 16, 1998Date of Patent: October 24, 2000Assignee: Vertex Pharmaceuticals IncorporatedInventors: Roy A. Black, Paul R. Sleath, Shirley R. Kronheim
-
Patent number: 5756465Abstract: There is disclosed an isolated polypeptide and derivatives thereof having protease biological activity for human precursor IL-1.beta. and for a substrate comprising:R.sub.1 -Asp-R.sub.2 -R.sub.3wherein R.sub.1 and R.sub.3 are independently any D or L isomer amino acid, R.sub.2 is Ala or Gly, and wherein the specific protease cleavage site is between Asp and R.sub.2. Inhibitor compounds, compositions and methods for inhibiting Interleukin 1.beta. protease activity are also disclosed. The inhibitor compounds comprise an amino acid sequence of from 1 to about 5 amino acids having an N-terminal blocking group and a C-terminal Asp residue connected to an electronegative leaving group, wherein the amino acid sequence corresponds to the sequence Ala-Tyr-Val-His-Asp.Type: GrantFiled: May 12, 1995Date of Patent: May 26, 1998Assignee: SanofiInventors: Paul R. Sleath, Roy A. Black, Shirley R. Kronheim
-
Patent number: 5629285Abstract: Compounds and methods are disclosed that are useful in inhibiting the TNF-.alpha. converting enzyme (TACE) responsible for cleavage of TNF-.alpha. precursor to provide biologically active TNF-.alpha.. The compounds employed in the invention are peptidyl derivatives having active groups capable of inhibiting TACE such as, hydroxamates, thiols, phosphoryls and carboxyls.Type: GrantFiled: May 22, 1996Date of Patent: May 13, 1997Assignee: Immunex CorporationInventors: Roy A. Black, Jeffrey N. Fitzner, Paul R. Sleath
-
Patent number: 5594106Abstract: Compounds and methods are disclosed that are useful in inhibiting the TNF-.alpha. converting enzyme (TACE) responsible for cleavage of TNF-.alpha. precursor to provide biologically active TNF-.alpha.. The compounds employed in the invention are peptidyl derivatives having active groups capable of inhibiting TACE such as, hydroxamates, thiols, phosphoryls and carboxyls.Type: GrantFiled: August 18, 1994Date of Patent: January 14, 1997Assignee: Immunex CorporationInventors: Roy A. Black, Jeffrey N. Fitzner, Paul R. Sleath
-
Patent number: 5416013Abstract: There is disclosed an isolated polypeptide and derivatives thereof having protease biological activity for human precursor IL-1.beta. and for a substrate comprising:R.sub.1 - Asp - R .sub.2 - R.sub.3wherein R.sub.1 and R.sub.3 are independently any D or L isomer amino acid, R.sub.2 is Ala or Gly, and wherein the specific protease cleavage site is between Asp and R.sub.2. Inhibitor compounds, compositions and methods for inhibiting Interleukin 1.beta. protease activity are also disclosed. The inhibitor compounds comprise an amino acid sequence of from 1 to about 5 amino acids having an N-terminal blocking group and a C-terminal Asp residue connected to an electronegative leaving group, wherein the amino acid sequence corresponds to the sequence Ala-Tyr-Val-His-Asp.Type: GrantFiled: February 28, 1994Date of Patent: May 16, 1995Assignee: Sterling Winthrop Inc.Inventors: Roy A. Black, Paul R. Sleath, Shirley R. Kronheim